Science ❯ Biotechnology

Drug Discovery

Artificial Intelligence Clinical Research AI Applications AI in Healthcare AI in Medicine Cancer Research Antibody Development Bioengineering Clinical Studies Therapeutics Virtual Cell Modeling Global Firms Optogenetics Targeted Therapy Molecular Simulation Therapeutic Agents Proprietary Platforms Computational Modeling Regulatory Science Molecular Licensing Recombinant Cells Clinical Trials

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

The Phase 1/2 asset targets PIK3CA‑mutant tumors to improve tolerability in HR+/HER2‑ breast cancer with closing expected in the first half of 2026.

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

Chai Discovery Raises $130 Million Series B at $1.3 Billion Valuation

Google Launches Interactions API and Upgraded Gemini Deep Research for Developers

Eli Lilly Halts Diabetes Arm of Bimagrumab Obesity Trial Weeks After Launch

Integrated Biosciences’ Optogenetic Platform Advances Toward Aging and Pan-Antiviral Therapies